In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Enanta Pharmaceuticals, Inc.. Trade Record

NASDAQ:ENTA Enanta Pharmaceuticals, Inc. stock gains 15.98% Exit Jul 7, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart ENTA Jun 12, 2017, priceSeries
About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Trade Information
Trade Type
Entry Date
Jun 12, 2017
Entry Price
Sell Date
Jul 7, 2017
Sell Price
Net Gain
Hold Time
18 Trading Days